FDA Authorises Pfizer-BioNTech Vaccine For 5-11 Yo Children!

FDA Authorises Pfizer-BioNTech Vaccine For 5-11 Yo Children!

The US FDA has officially authorised the Pfizer-BioNTech COVID-19 vaccine for use in 5-11 year-old children!

Here is what you need to know…

 

FDA Authorised Pfizer-BioNTech Vaccine For 5-11 Yo Children!

On 29 October 2021, the US FDA officially authorised the emergency use of the Pfizer-BioNTech COVID-19 vaccine in 5-11 year-old children.

This was based on their expert panel’s earlier approval, and their own evaluation of the data from Pfizer’s paediatric clinical trial.

Here is a short summary of the US FDA’s findings on the Pfizer-BioNTech vaccine for 5-11 year-old children :

Effectiveness : Immune responses of children 5 through 11 years of age were comparable to those of individuals 16 through 25 years of age. In addition, the vaccine was found to be 90.7% effective in preventing COVID-19 in children 5 through 11.

Safety : The vaccine’s safety was studied in approximately 3,100 children age 5 through 11 who received the vaccine and no serious side effects have been detected in the ongoing study.

Now that the FDA has approved the Pfizer-BioNTech vaccine for use in 5-11 year-old children, the US Centres for Disease Control and Prevention (CDC) will look into clinical recommendations for the vaccine.

I should point out that while the Pfizer paediatric vaccine is a lower-dose, improved version of the vaccine used in adults and adolescents.

Read more : Pfizer COVID-19 Vaccine For Kids : What You Need To Know!

 

FDA Excerpts On Pfizer Vaccine Authorisation For 5-11 Yo Children

Here is a selection of excerpts from the full FDA press release on their authorisation of the Pfizer-BioNTech vaccine for use in 5-11 year-old children.

Dose

The Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age is administered as a two-dose primary series, 3 weeks apart, but is a lower dose (10 micrograms) than that used for individuals 12 years of age and older (30 micrograms).

Effectiveness

The immune responses of the younger age participants were comparable to the older participants. The vaccine was 90.7% effective in preventing COVID-19.

Safety

Commonly reported side effects in the clinical trial included injection site pain (sore arm), redness and swelling, fatigue, headache, muscle and/or joint pain, chills, fever, swollen lymph nodes, nausea and decreased appetite. More children reported side effects after the second dose than after the first dose. Side effects were generally mild to moderate in severity and occurred within two days after vaccination, and most went away within one to two days.

Stability + Storage

The FDA also authorized a manufacturing change for the vaccine to include a formulation that uses a different buffer; buffers help maintain a vaccine’s pH (a measure of how acidic or alkaline a solution is) and stability. This new formulation is more stable at refrigerated temperatures for longer periods of time, permitting greater flexibility for vaccination providers.

 

Please Support My Work!

Support my work through a bank transfer /  PayPal / credit card!

Name : Adrian Wong
Bank Transfer : CIMB 7064555917 (Swift Code : CIBBMYKL)
Credit Card / Paypal : https://paypal.me/techarp

Dr. Adrian Wong has been writing about tech and science since 1997, even publishing a book with Prentice Hall called Breaking Through The BIOS Barrier (ISBN 978-0131455368) while in medical school.

He continues to devote countless hours every day writing about tech, medicine and science, in his pursuit of facts in a post-truth world.

 

Recommended Reading

Go Back To > Health | Business | Tech ARP

 

Support Tech ARP!

Please support us by visiting our sponsors, participating in the Tech ARP Forums, or donating to our fund. Thank you!

Leave a Reply Cancel reply